Nutex Health financials
$210.10−1.24%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 |
|---|---|---|---|---|
| Revenue | $875.3M | $479.9M | $247.6M | $219.3M |
| Gross profit | $875.3M | $479.9M | $247.6M | $219.3M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | $275.6M | $137.8M | -$1.3M | -$406.6M |
| Net income | $70.8M | $52.1M | -$45.8M | -$424.8M |
| Net margin | 8.1% | 10.9% | −18.5% | −193.7% |
| Diluted EPS | $10.48 | $9.69 | $-10.39 | $-100.36 |
| EBITDA | $296.2M | $156.8M | $16.3M | $8.6M |
| Operating cash flow | $248.1M | $23.2M | $1.3M | $50.6M |
| Free cash flow | $245.6M | $20.8M | -$8.2M | $36.0M |
| Diluted shares | 6.8M | 5.5M | 4.4M | 4.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & equivalents | $185.6M | $40.6M | $22.0M | $34.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $319.2M | $307.6M | $258.7M | $246.1M |
| Total assets | $918.5M | $655.3M | $398.2M | $431.8M |
| Total liabilities | $495.1M | $466.8M | $319.1M | $311.4M |
| Shareholders' equity | $423.4M | $188.5M | $79.1M | $120.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology